NEW YORK (Reuters): The EU drug regulator is unlikely to decide whether to approve Russia’s Sputnik V coronavirus vaccine until at least the first quarter of 2022 because some data needed for the review is still missing, a source with knowledge of the matter said.
“An EMA decision by the end of the year is now absolutely impossible,” the source said, referring to the European Medicines Agency.
Already a subscriber? Log in
Get 20% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
